natgillin/translations-raw huggingface dataset:
Safety of Synflorix was also assessed in 50 children with SCD starting vaccination at 7-11 months of age, all of them receiving the booster vaccination, and in 50 children with SCD starting vaccination at 12-23 months of age.
Varnost cepiva Synflorix so ocenili tudi pri 50 otrocih z boleznijo srpastih celic, ki so začeli cepljenje v starosti od 7 do 11 mesecev (vsi so dobili tudi obnovitveni odmerek), in pri 50 otrocih z boleznijo srpastih celic, ki so začeli cepljenje v starosti od 12 do 23 mesecev.
Read the package leaflet before use Intramuscular use
Pred uporabo preberite priloženo navodilo!
A clinical study evaluated the immunogenicity of Synflorix in 2-dose or 3-dose primed subjects in four European countries.
S klinično študijo so ocenili imunogenost cepiva Synflorix po primarnem cepljenju z 2 odmerkoma ali 3 odmerki v štirih evropskih državah.
The OPA GMTs were similar or higher following a single dose than a 3-dose primary course in infants below 6 months of age, except for serotype 5.
GMT OPA so bile po enkratnem odmerku podobne ali višje kot po primarnem cepljenju dojenčkov mlajših od 6 mesecev s 3 odmerki, razen za serotip 5.
As for other vaccines administered intramuscularly, Synflorix should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding may occur following an intramuscular administration to these subjects.
Tako kot vsa intramuskularno rabljena cepiva je treba tudi Synflorix previdno dajati otrokom s trombocitopenijo ali kakšno motnjo koagulacije, saj se jim lahko po intramuskularnem injiciranju pojavi krvavitev.
See sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes.
Za informacije o zaščiti pred specifičnimi pnevmokoknimi serotipi glejte poglavji 4.4 in 5.1.
No direct cause-and-effect can be inferred from observational studies of this type.
Na podlagi takšnih opazovalnih študij ni mogoče neposredno sklepati o vzroku in posledici.
Children with a weakened immune system (such as due to human immunodeficiency virus (HIV) infection or immunosuppressive therapy) may not get the full benefit from Synflorix.
Zgodi se lahko, da otrokom z oslabelim imunskim sistemom (npr. zaradi okužbe z virusom humane imunske pomanjkljivosti (HIV) ali imunosupresivne terapije) cepivo Synflorix ne koristi v polni meri.
It is recommended that subjects who receive a first dose of Synflorix complete the full vaccination course with Synflorix.
Priporočljivo je, da otroci, ki dobijo prvi odmerek cepiva Synflorix, opravijo celotno cepljenje z njim.
Other medicines and Synflorix
Druga zdravila in cepivo Synflorix
Children with splenic dysfunction
Otroci z disfunkcijo vranice
As with other vaccines, the administration of Synflorix should be postponed in subjects suffering from acute severe febrile illness.
Tako kot druga cepljenja je treba tudi cepljenje s cepivom Synflorix odložiti pri otrocih, ki imajo akutno hudo vročinsko bolezen.
A booster (fourth) dose is recommended at least 6 months after the last primary dose (see sections 4.4 and 5.1).
Obnovitveni (četrti) odmerek je priporočljiv vsaj 6 mesecev po zadnjem primarnem odmerku (glejte poglavji 4.4 in 5.1).
Prophylactic administration of antipyretics before or immediately after vaccine administration can reduce the incidence and intensity of post-vaccination febrile reactions.
Profilaktična uporaba antipiretikov Profilaktična uporaba antipiretikov pred dajanjem cepiva ali tik po njem lahko zmanjša incidenco in izrazitost febrilnih reakcij po cepljenju.
Enhancement of antibody response to Hib-TT conjugate, diphtheria and tetanus antigens was observed.
Opazili so večje nastajanje protiteles proti Hib-TT konjugatu, davičnim in tetanusnim antigenom.
Contents of the pack and other information What Synflorix contains
Vsebina pakiranja in dodatne informacije Kaj vsebuje cepivo Synflorix
Use with other vaccines
Uporaba cepiva
Table 2: Numbers and percentages of subjects with first episodes of B-CAP occurring from 2 weeks after the administration of the 3rd dose of Synflorix or control vaccine and vaccine efficacy (ATP cohort)
Preglednica 2: Število in delež preiskovancev s prvo epizodo B-CAP, ki se je pojavila po dveh tednih ali več po cepljenju s tretjim odmerkom cepiva Synflorix ali kontrolnega cepiva ter učinkovitost cepiva (kohorta po protokolu) Synflorix
Epidemiological data
Epidemiološki podatki
GlaxoSmithKine Biologicals Kft. Homoki Nagy István utca 1.
GlaxoSmithKine Biologicals Kft. Homoki Nagy István utca 1. 2100 Gödöllö
The clinical consequences of the lower post-primary and post-booster immune responses observed after the 2-dose primary schedule are not known.
Klinične posledice manjšega poprimarnega in poobnovitvenega imunskega odziva po primarnem razporedu z 2 odmerkoma niso znane.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila: http://www.ema.europa.eu/
Average follow-up, from first vaccination, was 24 to 28 months for invasive disease and hospital-diagnosed pneumonia.
Povprečno spremljanje za invazivno bolezen in v bolnišnici diagnosticirano pljučnico je trajalo od 24 do 28 mesecev od prvega cepljenja.
If your child misses an injection, it is important that you make another appointment.
Če otrok zamudi predvideno injekcijo, je pomembno, da se dogovorite za nov datum obiska pri zdravniku.
• Suspension for injection
• Suspenzija za injiciranje
OPA GMTs were observed for all infants except lower antibody GMCs for serotypes 4, 5, 9V and the cross-reactive serotype 19A in very preterms and serotype 9V in preterms and lower OPA GMT for serotype 5 in very preterms.
GMC protiteles in GMT OPA, razen nižjih GMC protiteles za serotipe 4, 5, 9V in navzkrižno reaktivni serotip 19A pri zelo nedonošenih in serotip 9V pri nedonošenih ter nižjega GMT OPA za serotip 5 pri zelo nedonošenih.
The clinical relevance of these differences is unclear, as Synflorix was observed to be effective against IPD caused by serotype 6B in a doubleblind, cluster-randomized clinical study (see Table 1).
Klinični pomen teh razlik ni jasen, kajti v dvojno slepi, klastersko randomizirani klinični študiji je bilo cepivo Synflorix učinkovito proti IPB, ki jo je povzročil serotip 6B (glejte preglednico 1).
Before NIP
Pred NPC
In children as of 2 years of age, syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection.
Po vsakem cepljenju ali celo pred njim se pri otrocih starejših od 2 let lahko pojavi sinkopa (omedlevica), kot psihološki odziv na injiciranje z iglo.
The immune responses after the booster dose in this age group were generally similar to those observed after the booster dose in infants who had been primed with 3 doses below 6 months of age.
Imunski odzivi po obnovitvenem odmerku so bili v tej starostni skupini na splošno podobni kot po obnovitvenem odmerku pri dojenčkih, ki so primarno dobili 3 odmerke do 6. meseca starosti.
Immunogenicity of Synflorix containing the preservative 2-PE (presented in a 4-dose container) was assessed in healthy infants vaccinated at 6, 10 and 18 weeks of age and compared to those receiving Synflorix without added preservative (160 enrolled subjects per group).
Imunogenost cepiva Synflorix s konzervansom 2-PE (v vsebniku s 4 odmerki) so ocenili pri zdravih dojenčkih, cepljenih v starosti 6, 10 in 18 tednov, in jo primerjali z imunogenostjo pri dojenčkih, ki so prejeli cepivo Synflorix brez dodanega konzervansa (160 vključenih preiskovancev na skupino).
The assessment of potential efficacy against IPD pre-licensure was based on a comparison of immune responses to the seven serotypes shared between Synflorix and another pneumococcal conjugate vaccine for which protective efficacy was evaluated previously (i.e. 7-valent Prevenar), as recommended by the WHO.
V skladu s priporočili Svetovne zdravstvene organizacije je ocena potencialne učinkovitosti proti invazivni pnevmokokni bolezni pred pridobitvijo dovoljenja za promet temeljila na primerjavi imunskega odziva na sedem serotipov, ki so skupni cepivu Synflorix in drugemu pnevmokoknemu konjugiranemu cepivu, katerega zaščitna učinkovitost je bila predhodno ocenjena (tj. 7-valentno cepivo Prevenar).
Although there was no significant difference between the two groups in the percentages of subjects with antibody concentration ≥ 0.20 µg/ml (ELISA), the percentages of subjects for serotypes 6B and 23F were lower than for the other vaccine serotypes (Table 7 and Table 8).
Čeprav se odstotek preiskovancev s koncentracijo protiteles ≥0,20 µg/ml (ELISA) med skupinama ni bistveno razlikoval, so bili odstotki preiskovancev za serotipa 6B in 23F manjši kot za ostale serotipe v cepivu (preglednica 7 in preglednica 8).
Therefore the degree and duration of protection against invasive pneumococcal disease and otitis media due to these three serotypes in children of this age group following a single dose of Synflorix cannot be predicted.
Zato pri otrocih v tej starostni skupini ni mogoče napovedati stopnje in trajanja zaščite pred invazivno pnevmokokno boleznijo in vnetjem srednjega ušesa zaradi teh treh serotipov po enem samem odmerku cepiva Synflorix.
In the follow-up of the European study evaluating the 2-dose and 3-dose primary vaccination schedules, the persistence of antibodies at 36-46 months of age was demonstrated in subjects that had received a 2-dose primary series followed by a booster dose with at least 83.7% of subjects remaining seropositive for vaccine serotypes and the cross-reactive serotype 19A.
Med spremljanjem v evropski študiji, ki je ocenjevala primarno cepljenje po shemi z 2 in 3 odmerki, so prisotnost protiteles pri 36 do 46 mesecih starosti dokazali pri preiskovancih, ki so prejeli primarno zaporedje z 2 odmerkoma in nato obnovitveni odmerek; vsaj 83,7 % preiskovancev je ostalo seropozitivnih za serotipe v cepivu in za navzkrižno reaktivni serotip 19A.
In Quebec, Canada, Synflorix was introduced into the infant immunisation programme (2 primary doses to infants less than 6 months of age and a booster dose at 12 months) following 4.5 years of use of 7-valent Prevenar.
V Quebecu (Kanada) so cepivo Synflorix vpeljali v program cepljenja dojenčkov (2 primarna odmerka za dojenčke, mlajše od 6 mesecev, in obnovitveni odmerek po 12 mesecih) po 4,5 letih uporabe 7valentnega cepiva Prevenar.
It is also recommended to administer a medicine that lowers fever in children with convulsion disorders or with prior history of febrile convulsions.
Zdravila, ki znižujejo zvišano telesno temperaturo, je priporočljivo dati tudi otrokom, ki imajo konvulzivne motnje ali imajo v anamnezi vročinske krče.
1-dose and 2-dose containers 4 years
Enoodmerni vsebnik in vsebnik z 2 odmerkoma 4 leta
Based on almost 3 years of surveillance following Synflorix introduction, a matched case-control study reported a significant decrease in culture or PCR confirmed IPD due to any vaccine serotype, and IPD due to individual serotypes 6B, 14 and 19A.
Na podlagi skoraj 3-letnega spremljanja po uvedbi cepiva Synflorix je študija usklajenih primerov in kontrol ugotovila značilno zmanjšanje s kulturo ali PCR potrjene invazivne pnevmokokne bolezni zaradi katerega koli serotipa v cepivu ter invazivne pnevmokokne bolezni zaradi posameznih serotipov 6B, 14 in 19A.
Convulsions (including febrile convulsions)
Bolezni živčevja zelo pogosti zaspanost redki konvulzije (vključno s febrilnimi konvulzijami)
Based on immunological bridging of the functional vaccine response (OPA) of Synflorix with the 11-valent formulation used within POET, it is expected that Synflorix provides similar protective efficacy against pneumococcal AOM.
Glede na imunološko premoščanje funkcionalnega odziva na cepljenje (OPA) s cepivom Synflorix ter 11-valentne formulacije, uporabljene v POET, je pričakovati, da je zaščitna učinkovitost cepiva
In another large randomised double-blind trial (POET) conducted in the Czech Republic and in Slovakia, 4,907 infants (ATP cohort) received either the 11-valent investigational vaccine (11Pn-PD) containing the 10 serotypes of Synflorix (along with serotype 3 for which efficacy was not demonstrated) or a control vaccine (hepatitis A vaccine) according to a 3, 4, 5 and 12-15 months vaccination schedule.
V drugem velikem, randomiziranem, dvojno slepem preskušanju (POET), ki je potekalo na Češkem in Slovaškem je 4.907 dojenčkov (kohorta ATP) prejelo bodisi 11-valentno raziskovalno cepivo (11Pn-PD), ki je vsebovalo 10 serotipov cepiva Synflorix (skupaj s serotipom 3, za katerega učinkovitost ni dokazana) ali kontrolno cepivo (cepivo proti hepatitisu A), in sicer po shemi cepljenja
For C-CAP it was 15.1% (95% CI: -15.5; 37.6) and 26.3% (95% CI: 4.4; 43.2) respectively.
Za C-CAP je bila 15.1 % (95 % IZ: -15,5; 37,6) in 26,3 % (95 % IZ: 4,4; 43,2).
(1) The relative rate reduction indicates how much the incidence of IPD in children of ≤5 years of age was reduced in the Synflorix cohort (followed for 3 years after NIP introduction) versus age and season matched non-vaccinated historical cohorts (each followed for 3 year periods before introduction of Synflorix into NIP).
19A (1) Relativno zmanjšanje deleža kaže, koliko se je zmanjšala incidenca invazivne pnevmokokne bolezni pri otrocih v starosti ≤ 5 let v kohorti s cepivom Synflorix (spremljani 3 leta po uvedbi NPC) v primerjavi z necepljenima historičnima kohortama, usklajenima po starosti in sezoni (obe spremljani 3 leta pred uvedbo cepiva Synflorix v NPC).
EU/1/09/508/001 - pack of 1 without needle EU/1/09/508/002 - pack of 10 without needle EU/1/09/508/003 - pack of 1 with 1 needle EU/1/09/508/004 - pack of 10 with 10 needles EU/1/08/508/005 - pack of 1 with 2 needles EU/1/09/508/010 - pack of 50 without needle
EU/1/09/508/001- pakiranje po 1 brez igle EU/1/09/508/002- pakiranje po 10 brez igle EU/1/09/508/003- pakiranje po 1 in 1 iglo EU/1/09/508/004- pakiranje po 10 in 10 iglami EU/1/09/508/005- pakiranje po 1 in 2 iglama EU/1/09/508/010- pakiranje po 50 brez igle
• collapse (sudden onset of muscle floppiness), periods of unconsciousness or lack of awareness,
• kolaps (nenaden pojav mlahavosti mišic), obdobja nezavesti ali zmanjšanega zavedanja ter bledica ali modrikasta obarvanost kože
The estimated vaccine efficacy against any clinical episodes of otitis media regardless of aetiology was 33.6% (95% CI: 20.8;
Ocenjena učinkovitost cepiva proti katerikoli klinični epizodi vnetja srednjega ušesa, ne glede na etiologijo, je bila 33,6 % (95 % IZ: 20,8-44,3).
Clinical studies demonstrated that the immune responses and the safety profiles of the co-administered vaccines were unaffected, with the exception of the inactivated poliovirus type 2 response, for which inconsistent results were observed across studies (seroprotection ranging from 78% to 100%).
Izjema je odziv na inaktivirano cepivo proti poliovirusu tipa 2, za katero so v različnih študijah dobili nekonsistentne rezultate (serološka zaščita od 78 do 100 %).
How the vaccine is given
Koliko cepiva se uporabi
• pain, redness and swelling where the injection is given
• bolečine, pordelost in oteklina na mestu, kamor je bilo vbrizgano cepivo
Booster dose at 9-10 months of age
Obnovitveni odmerek v starosti od 9 do 10 mesecev
Overall, for each vaccine serotype at least 97.6% of subjects achieved ELISA antibody concentrations ≥ 0.20 µg/ml and at least 91.9% achieved OPA titres ≥ 8.
V celoti je, za vse serotipe v cepivu, vsaj 97,6 % preiskovancev doseglo koncentracijo protiteles z ELISA ≥ 0,2 µg/ml in vsaj 91,9 % jih je doseglo titre OPA ≥ 8.
CONDITIONS OR RESTRICTIONS REGARDING SYPPLY AND USE
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE
After the primary vaccination course, fever ≥38 °C and >39 °C was reported respectively in 86.1% and 14.7% of children receiving Synflorix and in 82.9% and 11.6% of children vaccinated with 7-valent Prevenar.
Po primarnem ciklusu cepljenja se je zvišana telesna temperatura ≥ 38 °C oziroma > 39 °C pojavila pri 86,1 % in 14,7 % otrok, ki so dobili cepivo Synflorix, in pri 82,9 % in 11,6 % otrok, ki so dobili 7-valentno cepivo Prevenar.
Safety of Synflorix was assessed in 83 HIV positive (HIV+/+) infants (asymptomatic or with mild symptoms according to WHO classification), 101 HIV negative infants born from HIV positive mothers (HIV+/-) and 50 infants with sickle cell disease (SCD), receiving primary vaccination.
Varnost cepiva Synflorix so ocenili pri 83 HIV-pozitivnih (HIV+/+) dojenčkih (asimptomatski ali z blagimi simptomi po razvrstitvi Svetovne zdravstvene organizacije), pri 101 HIV-negativnemu dojenčku, rojenemu HIV-pozitivni materi (HIV+/-), in pri 50 dojenčkih z boleznijo srpastih celic, ki so prejeli primarno cepljenje.
The administration of a fourth dose (booster dose) in the second year of life elicited an anamnestic antibody response as measured by ELISA and OPA for the vaccine serotypes and the cross-reactive serotype 19A demonstrating the induction of immune memory after the three-dose primary course.
Uporaba četrtega odmerka (obnovitvenega odmerka) v drugem letu življenja je izzvala anamnestičen odziv protiteles, merjeno z ELISA in OPA, za serotipe v cepivu in navzkrižno reaktivni serotip 19A, kar dokazuje indukcijo imunskega spomina po primarnem ciklusu s tremi odmerki.
Type or cause of AOM
Vrsta ali vzrok akutnega vnetja srednjega ušesa
≥ 0.20 µg/ml (ELISA)
≥ 0,20 µg/ml (ELISA) Po prvem odmerku
If not used immediately, the vaccine should be stored in a refrigerator (2°C - 8°C).
Če ni uporabljeno takoj, ga je treba shraniti v hladilniku (2 °C - 8 °C).
- infants aged 7-11 months: The vaccination schedule consists of two primary doses of 0.5 ml with an interval of at least 1 month between doses.
- Dojenčki, stari od 7 do 11 mesecev: Shema cepljenja mora obsegati 2 primarna odmerka po 0,5 ml z vsaj 1-mesečnim presledkom med odmerkoma.
In infants, the most common adverse reactions observed after primary vaccination were redness at the injection site and irritability which occurred after approximately 41% and 55% of all doses respectively.
Pri dojenčkih sta bila najpogostejša neželena učinka po primarnem cepljenju rdečina na mestu injiciranja in razdražljivost: rdečina se je pojavila po približno 41 % vseh odmerkov, razdražljivost pa po približno 55 % vseh odmerkov.
One month after the booster dose increases of ELISA antibody GMCs and OPA GMTs were seen for each vaccine serotype and the cross-reactive serotype 19A, indicative of immunological memory.
En mesec po obnovitvenem odmerku je bilo povečanje GMC protiteles z ELISA in GMT OPA opazno za vse serotipe v cepivu in za navzkrižno reaktivni serotip 19A, kar kaže imunološki spomin.
Synflorix can be given concomitantly with any of the following monovalent or combination vaccines [including DTPa-HBV-IPV/Hib and DTPw-HBV/Hib]: diphtheria-tetanus-acellular pertussis vaccine (DTPa), hepatitis B vaccine (HBV), inactivated polio vaccine (IPV), Haemophilus influenzae type b vaccine (Hib), diphtheria-tetanus-whole cell pertussis vaccine (DTPw), measles-mumps-rubella vaccine (MMR), varicella vaccine (V), meningococcal serogroup C conjugate vaccine (CRM197 and TT conjugates), meningococcal serogroups A, C, W-135 and Y conjugate vaccine (TT conjugate), oral polio vaccine (OPV) and oral rotavirus vaccine.
Synflorix je mogoče uporabiti sočasno s katerimkoli od naslednjih monovalentnih ali kombiniranih cepiv [vključno z DTPa-HBV-IPV/Hib in DTPw-HBV/Hib]: cepivom proti davici, tetanusu in oslovskemu kašlju (brezcelično) (DTPa), cepivom proti hepatitisu B (HBV), inaktiviranim cepivom proti poliu (IPV), cepivom proti Haemophilus influenzae tipa b (Hib), cepivom proti davici, tetanusu in oslovskemu kašlju (polnocelično) (DTPw), cepivom proti ošpicam, mumpsu in rdečkam (MMR),
PARTICULARS TO APPEAR ON THE OUTER PACKAGING VIAL, PACK OF 1, 10, 100
PODATKI NA ZUNANJI OVOJNINI VIALA, PAKIRANJE Z 1, 10, 100
For most vaccine serotypes and serotype 19A, group comparisons did not suggest any differences post-booster dose in ELISA antibody GMCs and OPA GMTs between the HIV+/+ and HIV-/- groups, or the HIV+/- and HIV-/- groups.
Za večino serotipov v cepivu in za serotip 19A primerjava skupin po obnovitvenem odmerku ni pokazala razlik v geometrični sredini koncentracije protiteles z ELISA ali geometrične sredine titrov OPA med skupinama HIV+/+ in HIV-/- ter med skupinama HIV+/- in HIV-/-.
Table 6: Comparative analysis between 7-valent Prevenar and Synflorix in percentage of subjects with antibody concentrations > 0.20 µg/ml one month post-dose 3
Preglednica 6: Primerjalna analiza 7-valentnega cepiva Prevenar in cepiva Synflorix po odstotkih preiskovancev, ki so imeli en mesec po 3. odmerku koncentracijo protiteles > 0,20 µg/ml
The following side effects may happen with this medicine:
Uporaba tega cepiva lahko povzroči naslednje neželene učinke:
Long-term persistence of antibodies has not been investigated after administration of a primary series in infants plus booster or after a 2-dose priming in older children.
Dolgotrajna prisotnost protiteles po uporabi primarnega zaporedja in obnovitvenega odmerka pri dojenčkih ali po primarno 2 odmerkih pri starejših otrocih ni raziskana.
3-6 micrograms
3-6 mikrogramov
In subjects that had received a 3-dose primary series followed by a booster dose, at least 96.5% of the subjects remained seropositive for vaccine serotypes and 86.4% for serotype 19A.
Med preiskovanci, ki so prejeli primarno zaporedje s 3 odmerki in nato obnovitveni odmerek, je ostalo za serotipe v cepivu seropozitivnih vsaj 96,5 % preiskovancev, za serotip 19A pa 86,4 %.
In the FinIP study, vaccine effectiveness in reducing hospital-diagnosed pneumonia cases (identified based on the ICD 10 codes for pneumonia) was 26.7% (95% CI: 4.9; 43.5) in the 3+1 infant schedule and 29.3% (95% CI: 7.5; 46.3) in the 2+1 infant schedule.
V študiji FinIP je bila učinkovitost cepiva za zmanjšanje v bolnišnici diagnosticiranih primerov pljučnice (ugotovljene na podlagi kod MKB 10 za pljučnico) 26,7 % (95 % IZ: 4,9, 43,5) pri shemi za dojenčke 3+1 ter 29,3 (95 % IZ 7,5, 46,3) pri shemi za dojenčke 2+1.
The preferred sites are anterolateral aspect of the thigh in infants or the deltoid muscle of the upper arm in young children.
Pri dojenčkih je najprimernejše mesto za injiciranje anterolateralni del stegna, pri malih otrocih pa deltoidna mišica na nadlahti.
7-valent Prevenar Difference in % ≥ 0.20µg/ml (7valent Prevenar minus Synflorix)
Razlika v % ≥ 0,20 µg/ml (7valentni
A clinical study conducted in Burkina Faso assessed the immunogenicity of Synflorix administered to 146 children with SCD (haemoglobin SS disease, haemoglobin SC disease or with β-thalassemia) compared to 143 age-matched children without SCD.
V klinični študiji v Burkini Faso so ocenili imunogenost cepiva Synflorix pri 146 otrocih z boleznijo srpastih celic (boleznijo hemoglobina SS, boleznijo hemoglobina SC ali talasemijo β)
After primary vaccination, for the vaccine serotypes the percentages of subjects reaching antibody threshold and with OPA titres ≥ 8 were similar after 2-dose compared to 3-dose except lower OPA percentage for serotype 14.
Po primarnem cepljenju je bil delež otrok, ki so dosegli prag protiteles in titre OPA ≥ 8, za serotipe v cepivu podoben tako po cepljenju z 2 odmerkoma kot po cepljenju s 3 odmerki; izjema je bil nižji delež OPA za serotip 14.
Each 0.5 ml dose contains 1 microgram of polysaccharide for serotypes 1, 5, 6B, 7F, 9V, 14 and 23F, and 3 micrograms for serotypes 4, 18C and 19F
En 0,5-ml odmerek vsebuje 1 mikrogram polisaharida serotipov 1, 5, 6B, 7F, 9V, 14 in 23F ter 3 mikrograme serotipov 4, 18C in 19F.
After first opening of the 4-dose vial, the vaccine may be stored for a maximum of 28 days in a refrigerator (2°C - 8°C).
Po prvem odprtju viale s 4 odmerki je cepivo lahko shranjeno največ 28 dni v hladilniku (2 °C - 8 °C).
• unusual crying
• nenavaden jok